Emily is 48. She has a demanding job, two children, and aging parents who rely on her. Two years ago, she started forgetting words mid-sentence. Her heart would race without warning. She woke up at 2 a.m. every night, exhausted and anxious. She saw her doctor multiple times. Menopause never came up—and she was too embarrassed to say the word herself.
Like millions of women, Emily tried to power through until she couldn’t. Only after she was close to leaving her job did she find a clinician who listened and quickly connected the dots. Her symptoms were not unusual. The problem was that the system was not designed for her.
Emily’s story is not an exception; it is an operating pattern. Across life stages—adolescence, fertility, pregnancy, perimenopause, menopause, and beyond—healthcare has been built on an implicit assumption: women are “small men.” The result is a structural gap that shows up in delayed diagnoses, inconsistent treatment, and worse outcomes.
The costs are not just clinical; they are economic. Women make roughly 80% of household health decisions, yet the system defaults to male physiology. That misalignment reverberates across families, employers, insurers, and the broader private sector.
To understand the scale of the opportunity, one analysis looked at four conditions where women face major gaps in diagnosis and treatment but where effective solutions already exist today: menopause, osteoporosis, Alzheimer’s disease, and cardiovascular disease.
The finding is striking: if women received today’s standard of care in just these four areas, the private sector could unlock more than $100 billion in value by 2030. That value comes from higher productivity, fewer medical complications, reduced caregiving burden, and lower healthcare costs.
Reframing women’s health as both a clinical imperative and an economic growth opportunity changes the conversation. This is not a niche “women’s issue.” It is a mainstream innovation and productivity agenda.
A core theme emerging from innovators in women’s health is the idea of “making the invisible visible.” Glucose levels, sleep architecture, brain activity, hormonal patterns—all of these have historically been hard to measure in everyday life. Today, that is changing.
Three domains illustrate what’s possible when invisible signals are captured continuously and interpreted intelligently.
These tools are already reshaping behavior and expectations. In the U.S., 55% of women now track at least one health metric digitally, and women are the majority of users for several fast-growing diagnostics and wearables. Many no longer accept episodic, clinic-centered care as the default; they expect continuous, at-home insight with clinical-grade quality.
By 2030, an estimated 80% of health data will be consumer-generated. That creates unprecedented visibility—and immense risk of noise, confusion, and clinician overload. The strategic question is no longer how to gather data; it is how to convert it into meaningful, usable intelligence for both women and their providers.
Leading innovators are converging on several design principles:
Perimenopause is a powerful example. Traditionally, diagnosis is based on age and symptoms, sometimes a single blood test taken whenever a woman happens to secure an appointment. Yet perimenopause can last seven to ten years, and the hormonal profile at the outset is very different from the profile in the final months before menopause.
Using longitudinal hormone data from thousands of cycles, UVA developed an algorithm that can stratify women into distinct phases of perimenopause with roughly 88% accuracy, within a three-month window. That allows:
Similar pattern-based approaches are emerging in sleep and neurodegeneration. Deep sleep appears to play a critical role in clearing toxic proteins associated with Alzheimer’s disease, and women—who make up two-thirds of people with Alzheimer’s—often experience sleep disruption in the perimenopausal years. By combining rich sleep data, AI, and clinical research, companies are working with pharmaceutical partners to develop precision therapies informed by women’s biology rather than extrapolated from male norms.
As women arrive in clinics armed with sleep charts, glucose curves, and hormone reports, clinicians are increasingly inundated. Without guidance, that influx of data can slow rather than accelerate care. For continuous, at-home tracking to become a true “front door” to the health system, providers must be partners, not afterthoughts.
That requires a deliberate strategy:
Some companies are building dedicated provider-facing capabilities—offering not just devices, but interpretive algorithms, integrated sleep apnea testing, and turnkey reports that fit into existing systems. Others, particularly in hormonal health, co-develop research and protocols with hundreds of clinics, ensuring that clinicians are equipped to respond when patients arrive empowered with new insights.
If women’s health is to move from early adopters to mainstream impact, trust, access, and equity are non-negotiable. That means addressing not only who products are designed for, but who can realistically use and afford them.
On the access side, reimbursement is pivotal. Dexterity with outcomes data and cost-effectiveness analysis has allowed continuous glucose monitoring to expand from a narrow focus on type 1 diabetes to include type 2 diabetes and gestational diabetes. Clinical studies demonstrating lower C-section rates, reduced preeclampsia risk, and better maternal-fetal outcomes have helped persuade payers to broaden coverage.
On the equity side, bias in both hardware and algorithms must be confronted early. Beacon, for example, engineered EEG sensors to perform consistently across hair types and skin tones and powered its FDA validation study with a majority of women. It also uses large, diverse datasets to train and iteratively improve AI models under a regulatory framework that allows for frequent, evidence-based updates—critical for capturing nuanced trajectories such as the different phases of perimenopause.
Equally important is a conceptual shift. The label “femtech” has often confined innovation to fertility and period tracking, reinforcing the notion that women’s health equals reproduction. Yet every woman, if she lives long enough, will traverse menopause, and all women face cardiovascular, metabolic, neurological, and mental health risks that are shaped by sex-specific biology and context.
What is needed is not “femtech” but comprehensive women’s care—spanning hormones, brain health, metabolism, sleep, and beyond, across income levels and geographies. That in turn demands better alignment among three actors: what women want, what clinicians can deliver, and what payers will support. Until those incentives converge, progress will remain fragmented.
Women’s health is at an inflection point. The core science for many breakthroughs already exists; the frontier is execution. For leaders across healthcare, technology, and the private sector, several practical imperatives stand out:
The future of women’s health will not be defined by a single device or therapy. It will be defined by how well we learn to listen to women’s bodies—capturing the signals they already generate, decoding them with rigor, and returning intelligence that women can use to live not just longer, but better. The tools are here. What remains is the will to redesign the system around them.